Editorial comment to postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy.

prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J. Urol. 2008; 179: 1811–17. 18 Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J. Urol. 2004; 172 (6 Pt 1): 2227–31. 19 Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354–60. 20 Gandaglia G, Suardi N, Gallina A et al. Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. J. Urol. 2012; 187: 569–74. 21 Wille S, Heidenreich A, Hofmann R, Engelmann U. Preoperative erectile function is one predictor for post prostatectomy incontinence. Neurourol. Urodyn. 2007; 26: 140–3. 22 Gacci M, Lapini A, Serni S et al. Predictors of quality of life after radical treatment for prostate cancer. Urol. Int. 2008; 80: 231–6. 23 Goode PS, Burgio KL, Johnson TM II et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA 2011; 305: 151–9. 24 Ribeiro LH, Prota C, Gomes CM et al. Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. J. Urol. 2010; 184: 1034–9. 25 Abdollah F, Sun M, Suardi N et al. Prediction of functional outcomes after nerve-sparing radical prostatectomy: results of conditional survival analyses. Eur. Urol. 2012; 62: 42–52. 26 John H, Suter S, Hauri D. Effect of radical prostatectomy on urethral blood flow. Urology 2002; 59: 566–9. 27 Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J. Urol. 2010; 183: 629–33. 28 Gacci M, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 2012; 61: 994–1003. 29 Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int. J. Androl. 2009; 32: 587–98. 30 Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J. Endocrinol. Invest. 2011; 34: 557–67. 31 Morelli A, Filippi S, Sandner P et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J. Sex. Med. 2009; 6: 1594–608. 32 Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front. Horm. Res. 2009; 37: 108–22. 33 Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med. Care 1998; 36: 1002–12.